Identification of potential inhibitors targeting Ebola virus VP35 protein: a computational strategy

References

• Baell, J. B., & Holloway, G. A. (2010). New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. Journal of Medicinal Chemistry, 53(7), 2719–2740. https://doi.org/10.1021/jm901137j
   PubMed Web of Science ®Google Scholar
• Baig, M. H., Ahmad, K., Rabbani, G., Danishuddin, M., & Choi, I. (2018). Computer aided drug design and its application to the development of potential drugs for neurodegenerative disorders. Current Neuropharmacology, 16(6), 740–748. https://doi.org/10.2174/1570159X15666171016163510
   PubMed Web of Science ®Google Scholar
• Basler, C. F., Wang, X., Mühlberger, E., Volchkov, V., Paragas, J., Klenk, H. D., García-Sastre, A., & Palese, P. (2000). The Ebola virus VP35 protein functions as a type I IFN antagonist. Proceedings of the National Academy of Sciences of the United States of America, 97(22), 12289–12294. https://doi.org/10.1073/pnas.220398297
   PubMed Web of Science ®Google Scholar
• Bray, M., & Geisbert, T. W. (2005). Ebola virus: The role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. The International Journal of Biochemistry & Cell Biology, 37(8), 1560–1566. https://doi.org/10.1016/j.biocel.2005.02.018
   PubMed Web of Science ®Google Scholar
• Brown, C. S., Lee, M. S., Leung, D. W., Wang, T., Xu, W., Luthra, P., Anantpadma, M., Shabman, R. S., Melito, L. M., MacMillan, K. S., Borek, D. M., Otwinowski, Z., Ramanan, P., Stubbs, A. J., Peterson, D. S., Binning, J. M., Tonelli, M., Olson, M. A., Davey, R. A., … Amarasinghe, G. K. (2014). In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. Journal of Molecular Biology, 426(10), 2045–2058. https://doi.org/10.1016/j.jmb.2014.01.010
   PubMed Web of Science ®Google Scholar
• Burke, J., Declerq, R., Ghysebrechts, G., Pattyn, S. R., Piot, P., Ronsmans, M., Ruppol, J. F., Thonon, D., Van Der Groen, G., Van Nieuwenhove, S., Witvrouwen, M., Colbourne, G., Courtois, D., Dujeu, G., Germain, M., Raffier, G., Sureau, P., Vita, K., Koth, A.,… & Adrien, S. (1978). Ebola hemorrhagic-fever in Zaire, 1976-report of an International-Commission. Bulletin of the World Health Organization, 56(2), 271–293.
   PubMed Web of Science ®Google Scholar
• Cheng, F., Li, W., Zhou, Y., Shen, J., Wu, Z., Liu, G., Lee, P. W., & Tang, Y. (2012). admetSAR: A comprehensive source and free tool for assessment of chemical ADMET properties. Journal of Chemical Information and Modeling, 52(11), 3099–3105. https://doi.org/10.1021/ci300367a
   PubMed Web of Science ®Google Scholar
• Cole, J. C., Wiggin, S., & Stanzione, F. (2019). New insights and innovation from a million crystal structures in the Cambridge Structural Database. Structural Dynamics (Melville, N.Y.), 6(5), 054301. https://doi.org/10.1063/1.5116878
   PubMedGoogle Scholar
• Cui, T., & Zhang, J. (2015, October). Bioinformatics analysis of Zaire Ebola virus evolution [Paper presentation]. 2015 8th International Conference on Biomedical Engineering and Informatics (BMEI), In (pp. 435–439). IEEE. https://doi.org/10.1109/BMEI.2015.7401544
   Google Scholar
• Denis, M., Anita, K. M., Hilde, D. C., Stephan, G., & Johan, V. G. (2019). Ebola virus disease. Lancet, 393, 936–948.
   PubMed Web of Science ®Google Scholar
• Essmann, U., Perera, L., Berkowitz, M. L., Darden, T., Lee, H., & Pedersen, L. G. (1995). A smooth particle mesh Ewald method. The Journal of Chemical Physics, 103(19), 8577–8593. https://doi.org/10.1063/1.470117
   Web of Science ®Google Scholar
• Fanunza, E., Frau, A., Corona, A., & Tramontano, E. (2019). Insights into Ebola virus VP35 and VP24 interferon inhibitory functions and their initial exploitation as drug targets. Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders), 19(4), 362–374.
   PubMedGoogle Scholar
• Fausther-Bovendo, H., & Kobinger, G. (2021). Vaccine innovation spurred by the long wait for an Ebola virus vaccine. The Lancet. Infectious Diseases, 21(4), 440–441. https://doi.org/10.1016/S1473-3099(20)30515-6
   PubMed Web of Science ®Google Scholar
• Geisbert, T. W., & Hensley, L. E. (2004). Ebola virus: New insights into disease aetiopathology and possible therapeutic interventions. Expert Reviews in Molecular Medicine, 6(20), 1–24. https://doi.org/10.1017/S1462399404008300
   PubMedGoogle Scholar
• Gire, S. K., Goba, A., Andersen, K. G., Sealfon, R. S. G., Park, D. J., Kanneh, L., Jalloh, S., Momoh, M., Fullah, M., Dudas, G., Wohl, S., Moses, L. M., Yozwiak, N. L., Winnicki, S., Matranga, C. B., Malboeuf, C. M., Qu, J., Gladden, A. D., Schaffner, S. F., … Sabeti, P. C. (2014). Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science (New York, N.Y.), 345(6202), 1369–1372. https://doi.org/10.1126/science.1259657
   PubMed Web of Science ®Google Scholar
• Halgren, T. A. (1996). Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. Journal of Computational Chemistry, 17(5-6), 490–519. https://doi.org/10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P
   Web of Science ®Google Scholar
• Hess, B., Bekker, H., Berendsen, H. J., & Fraaije, J. G. (1997). LINCS: A linear constraint solver for molecular simulations. Journal of Computational Chemistry, 18(12), 1463–1472. https://doi.org/10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Web of Science ®Google Scholar
• Irwin, J. J., Sterling, T., Mysinger, M. M., Bolstad, E. S., & Coleman, R. G. (2012). ZINC: A free tool to discover chemistry for biology. Journal of Chemical Information and Modeling, 52(7), 1757–1768. https://doi.org/10.1021/ci3001277
   PubMed Web of Science ®Google Scholar
• Iversen, P. L., Kane, C. D., Zeng, X., Panchal, R. G., Warren, T. K., Radoshitzky, S. R., Kuhn, J. H., Mudhasani, R. R., Cooper, C. L., Shurtleff, A. C., Nasar, F., Sunay, M. M., Duplantier, A. J., Eaton, B. P., Zumbrun, E. E., Bixler, S. L., Martin, S., Meinig, J. M., Chiang, C.-Y., … Saunders, D. L. (2020). Recent successes in therapeutics for Ebola virus disease: No time for complacency. The Lancet. Infectious Diseases, 20(9), e231–e237. https://doi.org/10.1016/S1473-3099(20)30282-6
   PubMed Web of Science ®Google Scholar
• Jain, S., Martynova, E., Rizvanov, A., Khaiboullina, S., & Baranwal, M. (2021). Structural and functional aspects of Ebola virus proteins. Pathogens (Basel, Switzerland), 10(10), 1330. https://doi.org/10.3390/pathogens10101330
   PubMed Web of Science ®Google Scholar
• Jasial, S., Hu, Y., & Bajorath, J. (2017). How frequently are pan-assay interference compounds active? Large-scale analysis of screening data reveals diverse activity profiles, low global hit frequency, and many consistently inactive compounds. Journal of Medicinal Chemistry, 60(9), 3879–3886. https://doi.org/10.1021/acs.jmedchem.7b00154
   PubMed Web of Science ®Google Scholar
• Kawai, T., & Akira, S. (2007). Antiviral signaling through pattern recognition receptors. Journal of Biochemistry, 141(2), 137–145. https://doi.org/10.1093/jb/mvm032
   PubMed Web of Science ®Google Scholar
• Khabbaz, R., Bell, B. P., Schuchat, A., Ostroff, S. M., Moseley, R., Levitt, A., & Hughes, J. M. (2015). Emerging and reemerging infectious disease threats. In Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, 158. Elsevier Saunders.
   Google Scholar
• Khan, A., Khan, S. A., Zia, K., Altowyan, M. S., Barakat, A., & Ul-Haq, Z. (2022). Deciphering the impact of mutations on the binding efficacy of SARS-CoV-2 omicron and delta variants with human ACE2 receptor. Frontiers in Chemistry, 10, 892093. https://doi.org/10.3389/fchem.2022.892093
   PubMed Web of Science ®Google Scholar
• Khan, S. A., Khan, A., Zia, K., Shawish, I., Barakat, A., & Ul-Haq, Z. (2022). Cheminformatics-based discovery of potential chemical probe inhibitors of omicron spike protein. International Journal of Molecular Sciences, 23(18), 10315. https://doi.org/10.3390/ijms231810315
   PubMed Web of Science ®Google Scholar
• Khan, S. A., Zia, K., Ashraf, S., Uddin, R., & Ul-Haq, Z. (2021). Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. Journal of Biomolecular Structure & Dynamics, 39(7), 2607–2616. https://doi.org/10.1080/07391102.2020.1751298
   PubMed Web of Science ®Google Scholar
• Leung, D. W., Ginder, N. D., Fulton, D. B., Nix, J., Basler, C. F., Honzatko, R. B., & Amarasinghe, G. K. (2009). Structure of the Ebola VP35 interferon inhibitory domain. Proceedings of the National Academy of Sciences of the United States of America, 106(2), 411–416. https://doi.org/10.1073/pnas.0807854106
   PubMed Web of Science ®Google Scholar
• Leung, D. W., Prins, K. C., Borek, D. M., Farahbakhsh, M., Tufariello, J. M., Ramanan, P., Nix, J. C., Helgeson, L. A., Otwinowski, Z., Honzatko, R. B., Basler, C. F., & Amarasinghe, G. K. (2010). Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nature Structural & Molecular Biology, 17(2), 165–172. https://doi.org/10.1038/nsmb.1765
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A. (2000). Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological and Toxicological Methods, 44(1), 235–249. https://doi.org/10.1016/s1056-8719(00)00107-6
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2012). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 64, 4–17. https://doi.org/10.1016/j.addr.2012.09.019
   Web of Science ®Google Scholar
• Liu, G., Nash, P. J., Johnson, B., Pietzsch, C., Ilagan, M. X. G., Bukreyev, A., Basler, C. F., Bowlin, T. L., Moir, D. T., Leung, D. W., & Amarasinghe, G. K. (2017). A sensitive in vitro high-throughput screen to identify pan-filoviral replication inhibitors targeting the VP35–NP interface. ACS Infectious Diseases, 3(3), 190–198. https://doi.org/10.1021/acsinfecdis.6b00209
   PubMed Web of Science ®Google Scholar
• Luo, D., Zheng, R., Wang, D., Zhang, X., Yin, Y., Wang, K., & Wang, W. (2019). Effect of sexual transmission on the West Africa Ebola outbreak in 2014: A mathematical modelling study. Scientific Reports, 9(1), 1653. https://doi.org/10.1038/s41598-018-38397-3
   PubMedGoogle Scholar
• Meza, J. C. (2010). Steepest descent. WIREs Computational Statistics, 2(6), 719–722. https://doi.org/10.1002/wics.117
   Google Scholar
• Mirza, M. U., & Ikram, N. (2016). Integrated computational approach for virtual hit identification against ebola viral proteins VP35 and VP40. International Journal of Molecular Sciences, 17(11), 1748. https://doi.org/10.3390/ijms17111748
   PubMed Web of Science ®Google Scholar
• Molecular Operating Environment (MOE). (2018). Version 2018.0101; Chemical Computing Group Inc.: Montreal, QC, Canada.
   Google Scholar
• Mühlberger, E., Weik, M., Volchkov, V. E., Klenk, H. D., & Becker, S. (1999). Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. Journal of Virology, 73(3), 2333–2342. https://doi.org/10.1128/JVI.73.3.2333-2342.1999
   PubMed Web of Science ®Google Scholar
• O'Donnell, K. L., & Marzi, A. (2021). Immunotherapeutics for ebola virus disease: Hope on the horizon. Biologics: Targets & Therapy, 15, 79–86. https://doi.org/10.2147/BTT.S259069
   PubMedGoogle Scholar
• Olukitibi, T. A., Ao, Z., Mahmoudi, M., Kobinger, G. A., & Yao, X. (2019). Dendritic cells/macrophages-targeting feature of Ebola glycoprotein and its potential as immunological facilitator for antiviral vaccine approach. Microorganisms, 7(10), 402. https://doi.org/10.3390/microorganisms7100402
   PubMed Web of Science ®Google Scholar
• Qureshi, A. I. (2016). Clinical manifestations and laboratory diagnosis of Ebola virus infection. Ebola Virus Disease, 117. Academic Press.
   Google Scholar
• Rajak, H., Jain, D. K., Singh, A., Sharma, A. K., & Dixit, A. (2015). Ebola virus disease: Past, present and future. Asian Pacific Journal of Tropical Biomedicine, 5(5), 337–343. https://doi.org/10.1016/S2221-1691(15)30365-8
   Google Scholar
• Rastelli, G., Rio, A. D., Degliesposti, G., & Sgobba, M. (2010). Fast and accurate predictions of binding free energies using MM‐PBSA and MM‐GBSA. Journal of Computational Chemistry, 31(4), 797–810. https://doi.org/10.1002/jcc.21372
   PubMed Web of Science ®Google Scholar
• Rewar, S., & Mirdha, D. (2014). Transmission of Ebola virus disease: An overview. Annals of Global Health, 80(6), 444–451. https://doi.org/10.1016/j.aogh.2015.02.005
   PubMed Web of Science ®Google Scholar
• Rojas, M., Monsalve, D. M., Pacheco, Y., Acosta-Ampudia, Y., Ramírez-Santana, C., Ansari, A. A., Gershwin, M. E., & Anaya, J. M. (2020). Ebola virus disease: An emerging and re-emerging viral threat. Journal of Autoimmunity, 106, 102375. https://doi.org/10.1016/j.jaut.2019.102375
   PubMed Web of Science ®Google Scholar
• Sanchez, A. (2007). Analysis of filovirus entry into vero e6 cells, using inhibitors of endocytosis, endosomal acidification, structural integrity, and cathepsin (B and L) activity. The Journal of Infectious Diseases, 196 Suppl 2(s2), S251–S258. https://doi.org/10.1086/520597
   PubMedGoogle Scholar
• Saphire, E. O. (2020). A vaccine against Ebola virus. Cell, 181(1), 6.
   PubMed Web of Science ®Google Scholar
• Schmid, N., Eichenberger, A. P., Choutko, A., Riniker, S., Winger, M., Mark, A. E., & Van Gunsteren, W. F. (2011). Definition and testing of the GROMOS force-field versions 54A7 and 54B7. European Biophysics Journal: EBJ, 40(7), 843–856. https://doi.org/10.1007/s00249-011-0700-9
   PubMed Web of Science ®Google Scholar
• Schreiber-Stainthorp, W., Solomon, J., Lee, J. H., Castro, M., Shah, S., Martinez-Orengo, N., Reeder, R., Maric, D., Gross, R., Qin, J., Hagen, K. R., Johnson, R. F., & Hammoud, D. A. (2021). Longitudinal in vivo imaging of acute neuropathology in a monkey model of Ebola virus infection. Nature Communications, 12(1), 2855. https://doi.org/10.1038/s41467-021-23088-x
   PubMed Web of Science ®Google Scholar
• Stern, H. A. (2004). Simple algorithm for isothermal–isobaric molecular dynamics. Journal of Computational Chemistry, 25(5), 749–761. https://doi.org/10.1002/jcc.20001
   PubMed Web of Science ®Google Scholar
• Taylor, D. J., Leach, R. W., & Bruenn, J. (2010). Filoviruses are ancient and integrated into mammalian genomes. BMC Evolutionary Biology, 10(1), 193. https://doi.org/10.1186/1471-2148-10-193
   PubMedGoogle Scholar
• Wadood, A., Riaz, M., Uddin, R., & Ul-Haq, Z. (2014). In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening. PloS One, 9(2), e89109. https://doi.org/10.1371/journal.pone.0089109
   PubMed Web of Science ®Google Scholar
• Wilson, J. A., Bray, M., Bakken, R., & Hart, M. K. (2001). Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology, 286(2), 384–390. https://doi.org/10.1006/viro.2001.1012
   PubMed Web of Science ®Google Scholar
• Wittmann, T. J., Biek, R., Hassanin, A., Rouquet, P., Reed, P., Yaba, P., Pourrut, X., Real, L. A., Gonzalez, J. P., & Leroy, E. M. (2007). Isolates of Zaire ebolavirus from wild apes reveal genetic lineage and recombinants. Proceedings of the National Academy of Sciences of the United States of America, 104(43), 17123–17127. 104https://doi.org/10.1073/pnas.0704076104
   PubMed Web of Science ®Google Scholar
• Zia, K., Khan, S. A., Ashraf, S., Nur-e-Alam, M., Ahmed, S., & Ul-Haq, Z. (2021). Probing CAS database as prospective antiviral agents against SARS-CoV-2 main protease. Journal of Molecular Structure, 1231, 129953. https://doi.org/10.1016/j.molstruc.2021.129953
   PubMed Web of Science ®Google Scholar